Updated:
Exelixis
Exelixis is a multi-platform cancer company. It advances biotherapeutics and small molecule programs for the treatment of cancer. The company develops new...
Exelixis
Exelixis is a multi-platform cancer company. It advances biotherapeutics and small molecule programs for the treatment of cancer. The company develops new treatments for cancer patients and the people who care for them.
General information
Firm type
Asset Manager
Year founded
1994
Location
Region
North America
Country
United States
City
Alameda
Corporate office
Alameda, CA, United States
Principals
Michael M. Morrissey
President and CEO
Jeffrey J. Hessekiel
EVP, General Counsel and Secretary
P.J. Haley
EVP, Commercial
Susan M. Hubbard
EVP, Human Resources
Alan R. Shuldiner
EVP, R&D
Art Krieg
EVP, Biotherapeutics and Scientific Innovation
Tiffany L. Dass
EVP, Strategy and Corporate Affairs
Christopher J. Senner
EVP, CFO
Sector focus
Frequently asked questions
Who runs investment decisions at Exelixis?
Exelixis is a publicly traded biotech company, not a family office or asset manager. Strategic and capital allocation decisions are made by the CEO Michael Morrissey and the board of directors, all named on the corporate website. The firm allocates its internally generated cash flow to R&D pipelines, commercial infrastructure, and strategic partnerships rather than external fund-of-funds or direct deals outside oncology.
How does Exelixis generate its capital?
Exelixis generates revenue from the commercial sales of its approved drugs, CABOMETYX (cabozantinib) and COMETRIQ (cabozantinib). These drugs treat advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Licensing deals with Roche, Ipsen, and Takeda provide additional revenue outside the US. The company does not raise external fund capital.
What investment stages does Exelixis target?
Exelixis does not invest in external startups or funds. Its own R&D pipeline spans from preclinical discovery (small molecule and biotherapeutics) through Phase III clinical trials and commercial launch. It does not operate an external venture capital arm or co-invest alongside other LPs.
Is Exelixis structured as a family office or does it operate more like a biotech firm?
Exelixis is a publicly traded biotech company, with approximately 1,000 employees and a market cap in the billions. It is not a family office, and it does not manage capital for external investors. All financial decisions serve the public shareholders.
Which sectors does Exelixis explicitly avoid?
Exelixis focuses exclusively on oncology. It does not invest in other therapeutic areas such as cardiovascular, neurology, rare disease, or medical devices. The firm's pipeline is limited to small molecule inhibitors, antibody-drug conjugates, and bispecific antibodies all targeting cancer.
Does Exelixis maintain philanthropic structures, and how are they separated?
Exelixis has a community impact program described on its website under 'Our Impact,' covering employee volunteering and cause support, but it does not appear to have a separate philanthropic foundation. Charitable activities are part of the corporate entity and funded from operating cash.
Where is Exelixis headquartered?
Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda, CA 94502, in the San Francisco Bay Area. It also has a South San Francisco presence mentioned in earlier records. No other offices are disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: